Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
66 participants
INTERVENTIONAL
2008-10-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT01208090
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
NCT05725057
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
NCT00287118
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
NCT03706209
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
NCT02173301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ACT-128800
ACT-128800 administered orally once daily
B
Placebo
Matching placebo capsules administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACT-128800
ACT-128800 administered orally once daily
Placebo
Matching placebo capsules administered orally once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Systemic or topical treatments for psoriasis other than emollients.
* Ongoing bacterial, viral or fungal infections.
* History or presence of malignancy.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Actelion
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Actelion
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Albrecht Georg Schmidt, MD
Role: STUDY_DIRECTOR
Actelion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Landeskrankenhaus - Universitätsklilnikum Graz, Allgemeine Dermatologie
Graz, , Austria
University Klinik of Vienna
Vienna, , Austria
Departement de Pneumologie/ Unité Immunologie Clinique Allergie- Centre Hospitalier Lyon sud
Lyon, , France
CHU de Nice-Hôpital de l'Archet 2 / Service de dermatologie
Nice, , France
Dermatologie, Hôpital Purpan Universtité Paul Sabatier
Toulouse, , France
Klinik für Dermatologie Venerologie und Allergologie
Berlin, , Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Department of Dermatology University Hospital Johannes Gutenberg-University Mainz
Mainz, , Germany
University Clinic Münster Clinic and Policlinic for skin diseases
Münster, , Germany
Semmelweis Universtity Dept. dermato-venerology and skin oncology
Budapest, , Hungary
UNIVERSITY OF DEBRECEN Department of dermatology
Debrecen, , Hungary
University of Szeged Department of dermatology and allergology
Szeged, , Hungary
Veszprem County Csolnoky Ferenc Hospital Dermatology Department
Veszprém, , Hungary
Clinical Centre of Nis Clinic of Dermato-venerology
Niš, , Serbia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-058A200
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.